Tristan Ruhwedel

5PUBLICATIONS
11CO-AUTHORS
Predictive and prognostic markersMetabolic medicineHealth and ecological risk assessment
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (5)

|May 04, 2026
Multimodal Deep Learning for Prediction of Progression-Free Survival in Patients with Neuroendocrine Tumors Undergoing 177Lu-Based Peptide Receptor Radionuclide Therapy.

|Aug 28, 2025
AI-driven body composition monitoring and its prognostic role in mCRPC undergoing lutetium-177 PSMA radioligand therapy: insights from a retrospective single-center analysis.

Tristan Ruhwedel, Julian Rogasch, Markus Galler

|Mar 28, 2025
Beyond similarities: overall survival and prognostic insights from [¹⁷⁷Lu]Lu-DOTATOC therapy in neuroendocrine tumors.

Tristan Ruhwedel, Julian Rogasch, Imke Schatka

|Dec 23, 2023
Plasma Markers for Therapy Response Monitoring in Patients with Neuroendocrine Tumors Undergoing Peptide Receptor Radionuclide Therapy.

Christoph Wetz, Tristan Ruhwedel, Imke Schatka

|Feb 10, 2021
The Prognostic Value of the De Ritis Ratio for Progression-Free Survival in Patients with NET Undergoing [177Lu]Lu-DOTATOC-PRRT: A Retrospective Analysis.

Tristan Ruhwedel, Julian M M Rogasch, Kai Huang

Pageof 1

Frequent Collaborators

3 joint publications

Julian M Rogasch

3 joint publications

Holger Amthauer

2 joint publications

Christoph Wetz

1 joint publications

Kai Huang